- Companies
- Verily
Verily Funding, Investors & Competitors
Verily has raised $3.8B across 6 funding rounds, most recently a undisclosed-stage round in September 2026.
About Verily
Verily is a South San Francisco-headquartered Alphabet subsidiary advancing precision health through devices, software, and data platforms. Founded in 2015, it develops products like the Verily Study Watch for continuous health monitoring and Project Baseline for longitudinal research. Verily collaborates with Mayo Clinic and Novartis on cardiovascular studies and immune response projects, generating clinical evidence via AI analytics.
Founded
2015
HQ
Website
Status
Privately held
Customer focus
B2B
Revenue model
Subscription
Verily Funding History
Verily has raised a total of $3.8B across 6 funding rounds.
Verily's first fundraising round was a $800M undisclosed-stage round in January 2017. The most recent completed round was a undisclosed-stage round in September 2026.
Verily funding rounds
| Date | Stage | Investors | Raised | Deal Summary |
|---|---|---|---|---|
| Sep 2026 | Undisclosed stage | NVIDIA (lead); Series X Capital; UCHealth; University of Colorado Anschutz Medical Campus; Alphabet | - | - |
| Mar 2026 | Undisclosed stage | Series X Capital (lead); UCHealth; University of Colorado Anschutz Medical Campus; Alphabet | $300M | - |
| Sep 2022 | Strategic investment | Alphabet (lead) | $1B | Verily, Alphabet's life sciences subsidiary focused on precision health, announced a $1 billion investment round on September 9, 2022, led by parent company Alphabet. The funds will support expansion in real-world evidence generation, healthcare data platforms, research, care, underlying technology, strategic partnerships, global business development, and potential acquisitions. Leadership changes include founder Andy Conrad transitioning to executive chairman and president Stephen Gillett promoted to CEO, effective January 2023. This follows Verily's prior $700M round in 2020, bringing total funding to $3.5B. Verily has pursued commercial growth through partnerships with entities like Mayo Clinic, Microsoft, and L’Oreal, and acquisitions such as SignalPath in 2021 to enhance its clinical trial platform. Alphabet does not break out Verily-specific financials; its 'Other Bets' segment, which includes Verily, reported $753M revenue for full-year 2021, up from $657M in 2020, amid a broader push toward profitability in health tech amid competition from players like Amazon. |
| Dec 2020 | Undisclosed stage | Temasek; Silver Lake; Ontario Teachers' Pension Plan; Alphabet | $700M | Verily, Alphabet's life sciences company based in South San Francisco, announced a $700 million investment round on December 17, 2020, from investors including Alphabet, Silver Lake, Temasek, Ontario Teachers’ Pension Plan, and others. The funding aims to accelerate key businesses like the Baseline Platform, which supported COVID-19 testing for nearly two million people across 351 locations, and Verily Health Platforms including Healthy at Work, Onduo for diabetes/hypertension/wellness, and Coefficient insurance. This marks Verily's third major round after $800 million in 2017 from Temasek and $1 billion in 2019 led by Silver Lake. The proceeds will expand population health, clinical care, chronic disease management, and life sciences programs in surgery, pathology, and immunology. Alphabet's 'Other Bets' segment, which includes Verily, reported $178 million in Q3 2020 revenue but with significant operating losses. |
| Jan 2019 | Undisclosed stage | Silver Lake (lead) | $1B | Verily, an Alphabet life sciences company based in South San Francisco, raised $1 billion in a private equity round in January 2019 led by Silver Lake, with participation from Ontario Teachers’ Pension Plan and other global investment firms. The funding supported growth in strategic areas including partnerships, global business development, and potential acquisitions. As part of the deal, Alphabet CFO Ruth Porat and Silver Lake's Egon Durban joined Verily’s operating board. The round brought Verily’s total funding to $1.8 billion at the time, following a prior $800 million investment from Temasek in 2017. Verily focuses on applying AI, data science, and clinical expertise to healthcare challenges like diabetes, vision deterioration, multiple sclerosis, Parkinson’s, and disease detection. A later $700 million round occurred in December 2020 from existing investors including Alphabet and Silver Lake to expand businesses like Baseline and Verily Health Platforms. |
| Jan 2017 | Undisclosed stage | Temasek (lead) | $800M | Verily Life Sciences, an Alphabet company focused on life sciences research and engineering, announced on January 26, 2017, that Temasek Holdings would invest $800 million in exchange for a minority stake. The investment aimed to support Verily's commercialization of healthcare solutions globally, with collaboration on expansion outside the US, and Temasek nominating a director to Verily's operating board. A majority of the funds were to be provided immediately, with the remainder in the second half of 2017. Temasek, a Singapore-based investment firm with a $180 billion portfolio, highlighted its focus on healthcare technology and North American ventures. |
Who has invested in Verily?
8 investors have backed Verily across its funding rounds, including Alphabet, Temasek, Silver Lake, UCHealth, Series X Capital and University of Colorado Anschutz Medical Campus.
Lead investors include NVIDIA, Series X Capital, Alphabet, Silver Lake and Temasek.
Verily Investors
| Investor | HQ | Rounds | Role | First check |
|---|---|---|---|---|
| 4 | Lead | Dec 2020 | ||
| 2 | Lead | Jan 2017 | ||
| 2 | Lead | Mar 2026 | ||
| 2 | Participant | Mar 2026 | ||
| 2 | Lead | Jan 2019 | ||
| 2 | Participant | Mar 2026 | ||
This data is available for Pro users. Sign up to see all 8 Verily investors. Start Free Trial | ||||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAcquisitions by Verily
Verily has acquired 2 companies to date.
Last acquisition by Verily was on September 29th 2022. Verily acquired Granular for undisclosed valuation.
Latest Acquisitions by Verily
| Description | Granular is a New York-based insurtech firm that delivers precision risk management solutions for self-insured employers through its stop-loss insurance products. The company leverages predictive analytics and actuarial modeling to forecast healthcare cost volatility and enable risk-sharing arrangements. Granular partners with reinsurers such as Swiss Re and Munich Re to underwrite policies that cover high-cost claimants. Headquartered in New York City since its founding in 2021, Granular serves mid-market employers across the United States with tailored benefit plans that integrate real-time data from claims and utilization patterns. | SignalPath is a first clinical research platform built by researchers for researchers, providing breakthrough software to clinical research sites for dramatically improving ease and efficiency of trial execution. Purpose-built platform designed for point-of-care use, enabling clinical research teams to focus on patients while achieving research goals. |
| HQ Country | ||
| HQ City | Philadelphia, PA | Raleigh, NC |
| Deal Date | 29 Sep 2022 | 17 Aug 2021 |
| Valuation | undisclosed | undisclosed |
| EV/Revenue | ||
| EV/EBITDA | ||
This data is available for Pro users. Sign up to see all Verily acquisitions and their M&A valuation multiples. Start Free Trial | ||
Investments by Verily
Verily has invested in 11 companies to date.
Latest investment by Verily was on May 1st 2022. Verily invested in The Public Health Company in their $35M Series A round.
Latest Investments by Verily
| Description | The Public Health Company is a Palo Alto-headquartered SaaS provider of biosecurity platforms for enterprises managing biological risks in labs, pharma, and healthcare. Founded in 2020, it delivers predictive threat intelligence and compliance tools integrated with IoT sensors, serving clients in North America and Europe. | Syllable is a no-code platform that equips teams to build and deploy AI agents for customer support and sales automation. It connects with over 100 third-party LLM providers such as OpenAI, Anthropic, and Google, alongside tools like Zendesk and HubSpot. San Francisco-headquartered since its 2023 founding, Syllable serves enterprises including Fortune 500 companies through scalable AI operations management. | Culture Biosciences is a San Francisco-headquartered biotech firm offering a cloud-connected biomanufacturing platform with robotic bioreactors. Its system enables parallel experimentation for process development in fermentation and cell culture, serving pharmaceutical and industrial biotech clients. Founded in 2016, the company has raised over $100 million in funding and operates a 20,000-square-foot facility in South San Francisco for high-throughput runs. | Marvin Behavioral Health is a Marina del Rey-based virtual care platform delivering teletherapy, guided meditations, and community programs tailored for healthcare workers. It collaborates with hospitals and health systems to support employee mental health through on-demand sessions addressing burnout and stress. Launched in 2020 amid the COVID-19 pandemic, the service integrates with employer wellness benefits for seamless access. | |
| HQ Country | |||||
| HQ City | San Francisco, CA | San Francisco, CA | San Francisco, CA | Los Angeles, CA | |
| Deal Date | 1 May 2022 | 7 Feb 2022 | 14 Oct 2021 | 11 May 2021 | |
| Round | Series A | Series C | Series B | Seed | |
| Raised | $35M | $40M | $80M | $6M | |
| Investors | Venrock; The General Partnership; Cleveland Capital Management; ImpactAssets | S32; TCV; Oak HC/FT | GRIDS Capital; Northpond Ventures; E14 Fund; Synthesis Capital; BoxGroup; Cultivian Sandbox Ventures; S32; The Production Board (TPB); Team Builder Ventures; Craft Ventures | Alexandria Venture Investments | |
| Valuation | undisclosed | undisclosed | $220M | undisclosed | |
| EV/Revenue | |||||
| EV/EBITDA | |||||
This data is available for Pro users. Sign up to see all Verily investments and their VC round multiples. Start Free Trial | |||||
Verily Competitors
Verily competitors include listed companies like IQVIA, ICON plc, Privia Health and Indegene, and private ones like Hippocratic AI and Innovaccer.
| Company | HQ | Status | Revenue | EBITDA | Valuation | Revenue Multiple |
|---|---|---|---|---|---|---|
| Private | - | - | $3.5B | - | ||
| Publicly listed | $16B | $3.4B | $44B | 3.4x | ||
| Publicly listed | $8.3B | $816M | $13B | 1.9x | ||
| Private | $250M | - | $3.5B | 13.8x | ||
| Publicly listed | $2.1B | $44M | $2.6B | 0.9x | ||
| Publicly listed | $366M | $68M | $1.5B | 3.3x |
Verily Public Comps
Verily is still privately-owned, but its public comps include Palantir, Snowflake, Z.ai, IQVIA, Veeva, IDEXX Laboratories, Roper Technologies, GE HealthCare, Revvity and IonQ.
| Last FY | EV/Revenue | EV/EBITDA | ||||||
|---|---|---|---|---|---|---|---|---|
| Revenue | EBITDA | Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| $4.5B | $1.5B | 92.6x | 58.1x | 285.0x | 97.4x | |||
| $4.7B | ($1.3B) | 25.6x | 21.0x | (94.1x) | 121.7x | |||
| $108M | ($658M) | 422.9x | 65.9x | (69.4x) | (73.0x) | |||
| $16B | $3.4B | 3.6x | 3.4x | 17.2x | 14.8x | |||
| $3.2B | $965M | 11.1x | 10.2x | 36.9x | 22.4x | |||
| $4.3B | $1.5B | 9.5x | 8.9x | 27.1x | 24.9x | |||
| $7.9B | $3.2B | 6.1x | 5.7x | 15.2x | 14.6x | |||
| $21B | $3.7B | 1.8x | 1.8x | 10.1x | 10.0x | |||
This data is available for Pro users. Sign up to see all Verily competitors and their valuation data. Start Free Trial | ||||||||
Common questions about Verily
| When was Verily founded? | Verily was founded in 2015. |
| Where is Verily headquartered? | Verily is headquartered in San Francisco, CA, United States. |
| Is Verily publicly listed? | No, Verily is a private, VC-backed company. |
| How much funding has Verily raised? | Verily has raised $3.8B across 6 funding rounds. |
| What was Verily's last funding round? | Verily's last funding round was a undisclosed-stage round in September 2026, led by NVIDIA. |
| Who are Verily's investors? | Verily's investors include Alphabet, Temasek, Series X Capital, UCHealth, Silver Lake, University of Colorado Anschutz Medical Campus, NVIDIA and Ontario Teachers' Pension Plan. |
| Which companies are comparable to Verily? | Companies comparable to Verily include Hippocratic AI, IQVIA, ICON plc, Innovaccer, Privia Health and Indegene. |
| How many companies has Verily acquired? | Verily has acquired 2 companies, including Granular and SignalPath. |
| How many companies has Verily invested in? | Verily has invested in 11 companies, including The Public Health Company, Syllable, Culture Biosciences, Marvin Behavioral Health, Genalyte, Mammoth Biosciences, Ciitizen and Quince Therapeutics. |
| What was Verily's last investment? | In May 2022, Verily invested in The Public Health Company's $35M Series A alongside Venrock, The General Partnership, Cleveland Capital Management and 1 other investor. |
See companies similar to Verily
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.




